A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05981703
• Other study ID #: BGB-A317-26808-101
• Secondary ID: CTR20240210
• Status: Recruiting
• Phase: Phase 1
• Start date: September 7, 2023
• Est. completion date: February 2027

Study information

• Verified date: June 2024
• Source: BeiGene
• Contact: Study Director
• Phone: 1.877.828.5568
• Email: clinicaltrials[@]beigene.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: February 2027
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection.

2. Eastern Cooperative Oncology Group (ECOG) Performance Status = 1.

3. Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors that are immune-sensitive who have been previously treated.

4. = 1 measurable lesion per RECIST v1.1.

5. Able to provide an archived tumor tissue sample.

6. Adequate organ function.

7. Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and for = 90 days after the last dose of BGB-26808 or for = 120 days after the last dose of tislelizumab.

8. Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study treatment period and for = 90 days after the last dose of BGB-26808 or for = 120 days after the last dose of tislelizumab.

Exclusion Criteria:

1. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention.

2. Clinically significant bleeding from the gastrointestinal tract within 28 days before the first dose of study treatment(s).

3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.

4. Active autoimmune diseases or history of autoimmune diseases that may relapse

5. Any malignancy = 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).

6. Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication = 14 days before the first dose of study treatment(s).

7. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases.

8. Uncontrolled diabetes.

9. Infection (including tuberculosis infection) requiring systemic (oral or intravenous) antibacterial, antifungal, or antiviral therapy = 14 days before the first dose of study treatment(s).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms
• Solid Tumor

Intervention

Drug:
• BGB-26808
Planned doses administered orally as a tablet daily.
• Tislelizumab
Planned doses administered by intravenous infusion.

Locations

Country	Name	City	State
Australia	Ashford Cancer Centre Research	Kurralta Park	South Australia
Australia	Southside Cancer Care	Miranda	New South Wales
Australia	Linear Clinical Research	Nedlands	Western Australia
Australia	Macquarie University	North Ryde	New South Wales
China	Jining No Peoples Hospital	Jining	Shandong
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai
China	The First Hospital of China Medical University Hunnan Branch	Shenyang	Liaoning
China	Hubei Cancer Hospital	Wuhan	Hubei
New Zealand	Auckland City Hospital	Auckland
United States	John Theurer Cancer Center Hackensack University Medical Center	Hackensack	New Jersey
United States	The University of Texas Md Anderson Cancer Center	Houston	Texas
United States	Yale University, Yale Cancer Center	New Haven	Connecticut
United States	Providence Portland Medical Center	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
BeiGene

Countries where clinical trial is conducted

United States,  Australia,  China,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)	Number of participants with AEs and SAEs, including findings from physical examinations, electrocardiograms (ECGs), laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.	Approximately 3 years
Primary	Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-26808	MTD is defined as the highest dose evaluated for which estimated toxicity rate is the closest to the target toxicity rate of 30%. MAD is defined as the highest dose administered if MTD is not reached.	Approximately 1.5 years
Primary	Phase 1a: Recommended Dose for Expansion (RDFE) of BGB-26808	RDFE of BGB-26808 alone or in combination with tislelizumab will be determined based upon the MTD or MAD.	Approximately 1.5 years
Primary	Phase 1b: Overall Response Rate (ORR)	ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.	Approximately 3 years
Secondary	Phase 1a: ORR	ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by the investigator using RECIST v1.1.	Approximately 2 years
Secondary	Phase 1a and 1b: Duration of Response (DOR)	DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first as assessed by the investigator.	Approximately 3 years
Secondary	Phase 1a and 1b: Disease Control Rate (DCR)	DCR is defined as the percentage of participants with best overall response of CR, PR, or stable disease. It will be summarized similarly as ORR as assessed by the investigator.	Approximately 3 years
Secondary	Phase 1a and 1b: Clinical Benefit Rate (CBR)	CBR is defined as the percentage of participants with best overall response of confirmed CR, PR, or stable disease lasting = 24 weeks as assessed by investigator.	Approximately 3 years
Secondary	Phase 1b: Progression Free Survival (PFS)	PFS is defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of progressive disease assessed by the investigator using RECIST v1.1 or death, whichever occurs first.	Approximately 3 years
Secondary	Phase 1a: Maximum observed plasma concentration (Cmax) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Minimum observed plasma concentration (Cmin) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Time to maximum plasma concentration (Tmax) for BGB-26808	Pharmacokinetic analysis for BGB-26808 concentrations, alone or in combination with tislelizumab. Single-dose and steady-state PK parameters.	Approximately 4 years
Secondary	Phase 1a: Half-life (t1/2) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Area under the concentration-time curve (AUC) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Apparent clearance (CL/F) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Apparent volume of distribution (Vz/F) for BGB-26808		Approximately 4 years
Secondary	Phase 1a: Accumulation ratio for BGB-26808		Approximately 4 years
Secondary	Phase 1b: Plasma concentrations of BGB-26808		Approximately 4 years
Secondary	Phase 1b: Number of Participants with AEs and SAEs	Number of participants with AEs and SAEs, including findings from physical examinations, ECGs, laboratory assessments, and that meet protocol-defined dose-limiting toxicity criteria.	Approximately 3 years